Merck's Investigational CETP-Inhibitor, MK-0859 - anacetrapib
Merck and Co. announced yesterday that in Phase IIb study results, anacetrapib significantly reduced LDL-cholesterol (LDL-C) and increased HDL-cholesterol (HDL-C) both alone and in combination with atorvastatin 20 mg compared to placebo in patients with dyslipidemia.
Several dosages were tested during the eight week study, from 10 to 300 mg. LDL-C levels were reduced from 16% to 40% and HDL-C levels were increased from 44% to 139%.
Dosages were also tested in combination with atorvastatin and produced significant incremental reductions in LDL-C and increases in HDL-C when compared to atorvastatin alone.
Another bright spot - there was no significant indication of raised blood pressure during the test.
Technorati Tags: Cholesterol LDL HDL anacetrapibatorvastatin
Several dosages were tested during the eight week study, from 10 to 300 mg. LDL-C levels were reduced from 16% to 40% and HDL-C levels were increased from 44% to 139%.
Dosages were also tested in combination with atorvastatin and produced significant incremental reductions in LDL-C and increases in HDL-C when compared to atorvastatin alone.
Another bright spot - there was no significant indication of raised blood pressure during the test.
Technorati Tags: Cholesterol LDL HDL anacetrapibatorvastatin
Labels: anacetrapib, atorvastatin, cholesterol, HDL, LDL
posted by Ken MacKenzie at 2:33 PM
0 Comments:
Post a Comment
<< Home